or Try an Advanced Search...

    ETF Components for SBIO - ALPS Medical Breakthroughs ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    CERE B 0.05 5.04
    VKTX B -1.86 4.79
    PCVX D 0.26 4.53
    RVMD A -2.57 4.01
    ALPN A -0.02 2.84
    ALKS F 0.38 2.67
    CRNX A -0.42 2.28
    AXSM F 3.18 2.19
    SWTX D -5.27 2.15
    XENE D -1.74 2.10
    IDYA D -1.22 2.04
    ACLX D -5.03 1.96
    ACAD F -1.41 1.89
    IMCR D 1.79 1.79
    SMMT D 0.00 1.67
    CLDX D -1.71 1.67
    CORT F 0.09 1.63
    DNLI F -3.67 1.62
    MRUS D -2.08 1.57
    VERA D -5.14 1.57
    RYTM D -0.68 1.56
    VCEL B -0.46 1.54
    ARVN D 1.14 1.53
    NTLA F 1.41 1.41
    KROS D -2.75 1.40
    GLPG F 0.48 1.31
    GERN A -1.07 1.31
    RNA A -1.43 1.28
    CPRX A -0.59 1.23
    SNDX D 1.76 1.22
    INBX C -0.09 1.10
    AGIO B 0.34 1.09
    EWTX D -2.27 1.04
    PTGX D 1.51 1.02
    RCUS F -1.55 0.97
    ZLAB F -0.35 0.96
    KURA D -0.90 0.95
    MORF F 1.64 0.94
    FDMT D 1.69 0.90
    TARS B -1.64 0.88
    VRNA F -3.11 0.88
    DAWN B -4.76 0.86
    IRWD F 4.47 0.83
    AKRO F 1.27 0.82
    DCPH D 2.39 0.81
    XNCR F -3.43 0.78
    PRTA F 2.58 0.77
    VIR F 0.38 0.76
    MIRM F 0.38 0.75
    MNKD D 2.59 0.74
    MGNX B -2.12 0.70
    LQDA D -3.84 0.69
    VRDN F -3.63 0.64
    BCRX F -1.56 0.64
    MDXG F 1.30 0.62
    ZNTL F 3.19 0.61
    ETNB F 1.58 0.59
    SPRY B -0.71 0.59
    OPK C 0.00 0.57
    PLRX F 2.05 0.54
    ARCT F -1.25 0.54
    IRON F -4.16 0.49
    AUPH F 3.74 0.49
    KNSA D -0.44 0.47
    SVRA C -1.15 0.47
    AVTE B 1.30 0.44
    ALLO F -0.29 0.40
    OLMA F 0.05 0.40
    CMPS F -0.83 0.38
    ANAB D -2.87 0.38
    ALEC F 0.00 0.34
    MLYS F 4.00 0.33
    FULC D -3.19 0.31
    TVTX F -1.12 0.31
    REPL F -7.32 0.30
    BMEA F -2.96 0.29
    ITOS D 2.52 0.27
    AURA F 0.71 0.24
    AVXL F -2.89 0.23
    ENTA C 0.00 0.22
    INZY F -1.75 0.20
    RAPT F 0.38 0.19
    VNDA A 4.23 0.16
    RPHM C -1.14 0.04

    Represented by ETF Holdings

    Keywords: Biopharmaceutical Medicine Biotechnology Cancer Life Sciences Disease Clinical Medicine Immunology Biology Clinical Development Organ Systems Immune System Autoimmune Disease Chemical Compounds Medication Solid Tumors Alcohol Alzheimer's Disease Antibodies Infectious Diseases
    Industries: Biotechnology Drug Manufacturers - Specialty & Generic Diagnostics & Research Drug Manufacturers - Major Medical Care Facilities Medical Devices

    Recent News for ALPS Medical Breakthroughs ETF & its Holdings

    Date Stock Title
    Apr 19 TARS Insider Returns Down To US$166k As Tarsus Pharmaceuticals' Stock Dips 14%
    Apr 19 MGNX We're Hopeful That MacroGenics (NASDAQ:MGNX) Will Use Its Cash Wisely
    Apr 18 VKTX Viking Therapeutics: An Oral Weight Loss Drug With More Data Ahead
    Apr 18 RNA To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
    Apr 18 FDMT To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
    Apr 18 ALLO To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
    Apr 18 CERE Heard on the Street: AbbVie’s Bet on a Neuroscience Drug Maker Just Got Better
    Apr 18 AUPH Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
    Apr 18 CPRX Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is largely controlled by institutional shareholders who own 65% of the company
    Apr 18 MIRM Stifel starts Mirum at buy, cites IBATi drug potential
    Apr 18 VNDA Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up
    Apr 18 VNDA Investors Heavily Search Vanda Pharmaceuticals Inc. (VNDA): Here is What You Need to Know
    Apr 18 ALPN Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?
    Apr 18 VIR Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
    Apr 18 CERE AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug
    Apr 18 AGIO Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
    Apr 18 SWTX SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
    Apr 18 CERE Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
    Apr 17 VKTX Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
    Apr 17 ACAD Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
    The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the Poliwogg Medical Breakthroughs IndexSM. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology and pharmaceutical companies that have one or more drugs in either Phase II or Phase III U.S. Food and Drug Administration clinical trials. It is non-diversified.
    Exchange Traded Fund ETF Index Fund Biotechnology Pharmaceutical Passive Management
    Back to the Main SBIO Page...